>
-Escient Pharmaceuticals Announces $120 Million Series C Financing-Fusion Enertech proporciona inversión en litio y soporte técnico de EDL para Argentina-Global Industrial Computers Market Is Expected to Generate $8.9 Billion by 2031: Allied Market Research-Silvano Fashion Group Consolidated Interim Financial Report for Q3 and 9 months of 2022 (unaudited)-Silvano Fashion Group 2022.aasta III kvartali ja 9 kuu konsolideeritud vahearuanne (auditeerimata)-Acciones del banco Santander ¿Buena o mala inversión en dividendos?-Flow Imaging Microscopy Market Size 2022, Industry Saturation, Share, Trends, Market Modification, and Expansion & Revolution Forecast till 2022 to 2032 : Quince Market Insights-Clear Sky Preliminary Data Review Completed by Processing Partner MDS-Report on Financial Results for the Three and Nine Months Ended September 30, 2022-Three Valley Copper Reports 2022 Third Quarter Results-Morgan Stanley Schedules Quarterly Investor Conference Call-Natuzzi S.p.A.: Third Quarter 2022 Financial Results and Shareholder Letter-Avante Logixx Inc. Announces Financial Results For The Second Fiscal Quarter Ended September 30, 2022-Pershing Square Holdings, Ltd. Announces Transactions in Own Shares – 25 November 2022-FEELM construye una fábrica ecológica con un sistema de gestión de la energía que reduce las emisiones de carbono en 500 toneladas-beaconsmind AG Announces the Postponement of the Publication of Its Annual Financial Report to December 16, 2022-Teleperformance SE: Statement on Transactions on Own Shares Carried out from November 18 to November 24, 2022 (inclusive)-The Korea Fund, Inc. Announces Invitation to Join a Webinar-Global Meat Substitutes Market Revenue is Predicted to Reach US$4.0 billion by 2027 – says MarketsandMarkets™-ZoomerMedia Limited Announces Declaration of Annual Dividend

Athersys to Host Business Update Conference Call on October 6th

CLEVELAND–()–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert “Willie” Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the company’s accomplishments since its recently announced restructuring.

In lieu of a live question and answer session, management encourages participants to submit questions in advance to ir@athersys.com. A replay of the event will be available in the Investors section of www.athersys.com.

About MultiStem®

MultiStem® (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique “off-the-shelf” stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Leave a Comment